We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-19.65%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$79.5M
AUM Growth
-$129M
Cap. Flow
+$18.1M
Cap. Flow %
22.76%
Top 10 Hldgs %
61.99%
Holding
120
New
40
Increased
18
Reduced
24
Closed
32

Sector Composition

Rank Sector Weight
1 Miscellaneous 56.22%
2 Healthcare 37.44%
3 Industrials 1.78%
4 Technology 1.66%
5 Consumer Discretionary 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TMDI
51
DELISTED
Titan Medical Inc. Ordinary Shares
TMDI
$265K 0.33%
+112,305
New +$281K
OPTT icon
52
Ocean Power Technologies
OPTT
$22.9M
$228K 0.29%
+3,977
New +$303K
CODX
53
Co-Diagnostics
CODX
$7.82M
$225K 0.28%
9,320
-16,458
-64% -$461K
MDGSW
54
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
$218K 0.27%
1,030,654
+16,067
+2% +$7.76K
RMTI icon
55
Rockwell Medical
RMTI
$31.4M
$217K 0.27%
+655
New +$333K
HYPD
56
Hyperion DeFi Inc
HYPD
$53.6M
$213K 0.27%
619
-200
-24% -$87.6K
TTNP
57
PUT
DELISTED
Titan Pharmaceuticals
TTNP
$211K 0.27%
3
+1
+50% +$914
OPGN
58
DELISTED
OpGen, Inc
OPGN
$204K 0.26%
130
-102
-44% -$199K
AVEO
59
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$189K 0.24%
+28,111
New +$241K
SHIPZ
60
DELISTED
Seanergy Maritime Holdings Corp Class B Warrant
SHIPZ
$178K 0.22%
+888,889
New +$248K
VKTX icon
61
CALL
Viking Therapeutics
VKTX
$3.54B
$166K 0.21%
200
-45
-18% -$385
CATX icon
62
Perspective Therapeutics
CATX
$312M
$152K 0.19%
37,061
-90,907
-71% -$381K
CSCI
63
PUT
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$137K 0.17%
+5
New +$1.76K
COGT icon
64
Cogent Biosciences
COGT
$5.73B
$133K 0.17%
12,731
-38,859
-75% -$517K
QNRX
65
Quoin Pharmaceuticals
QNRX
$13.6M
$124K 0.16%
2
ONTXW
66
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$115K 0.14%
642,312
+950
+0.1% +$143
CALA
67
DELISTED
Calithera Biosciences, Inc
CALA
$112K 0.14%
+1,440
New +$163K
XNTK icon
68
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.88B
$109K 0.14%
854
+354
+71% +$25.6K
ADXS
69
DELISTED
Advaxis Inc
ADXS
$87K 0.11%
+41,722
New +$132K
APDNW
70
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$86K 0.11%
21,504
-170,798
-89% -$1.86K
ALT icon
71
PUT
Altimmune
ALT
$632M
$85K 0.11%
233
-1,036
-82% -$2.77K
ALT icon
72
Altimmune
ALT
$632M
$81K 0.1%
+34,205
New +$91.5K
BNBX
73
PUT
DELISTED
BNB PLUS CORP
BNBX
0
CARM
74
PUT
DELISTED
Carisma Therapeutics
CARM
$70K 0.09%
+28
New +$838
RKDA icon
75
Arcadia Biosciences
RKDA
$1.03M
$61K 0.08%
+501
New +$107K

Similar funds

Sabby Management's Q2 2019 Portfolio in Review

As of Q2 2019, Sabby Management held 120 positions worth $79.5M, down 62% from $208M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management deployed $18.1M of net new capital in Q2 2019, opening 40 new positions and adding to 18 existing holdings. Its largest new stake was Seanergy Maritime Holdings: 10,437 shares worth $1.03M.

By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, down from 85% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Odonate Therapeutics, Inc. Common Stock, an estimated $2.41M trimmed.

  • Sabby Management's largest Q2 2019 buy was Seanergy Maritime Holdings: 10,437 shares worth $1.03M.
  • Sabby Management added most to Bridgeline Digital in Q2 2019, an estimated $625K increase.
  • Sabby Management's biggest Q2 2019 reduction was Odonate Therapeutics, Inc. Common Stock, cutting an estimated $2.41M.
  • Sabby Management fully exited Loop Industries in Q2 2019, selling an estimated $1.97M.
  • Sabby Management's ten largest holdings make up 62% of its $79.5M portfolio in Q2 2019.
  • Sabby Management opened 40 new positions and closed 32 in Q2 2019.
  • Sabby Management's portfolio value fell 62% quarter-over-quarter to $79.5M.

Based on Sabby Management's 13F filing for Q2 2019, filed 14 Aug 2019.